Investors & Media

What's new.

Press releases

Press releases.

August 20th 2024

Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024

August 14th 2024

Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody

August 7th 2024

Immutep to Participate in Upcoming Investor Conferences

more

Investor updates

Investor updates.

February 21st 2024

Investor Update - February 2024

August 18th 2023

Investor Update - August 2023

November 17th 2022

Investor Update - November 2022

more

Analyst reports

Analyst reports.

August 30th 2024

Jefferies - FY24: Adventure of a Lifetime; Buy, A$1.10 PT (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

August 23rd 2024

Bell Potter - Looking out for two LAG-3 ESMO Presentations; Maintain Buy, A$0.75 PT (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

August 16th 2024

Canaccord Genuity - IMM highlights efti's unique mechanism and upcoming news flow at CG Growth Conference; Maintain Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

more